{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:57:22Z","timestamp":1790647042771,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["WJ2019Q032 2019CFB495"],"award-info":[{"award-number":["WJ2019Q032 2019CFB495"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2019YFC1316203"],"award-info":[{"award-number":["2019YFC1316203"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Anthracycline-associated cardiotoxicity is frequently seen in cancer survivors years after treatment, but it is rare in patients on chemotherapy. This study aimed to investigate the clinical characteristics of cardiac disorders in children with acute lymphoblastic leukemia (ALL) during chemotherapy. A retrospective case study was conducted in children with ALL, for whom electrocardiogram (ECG) and echocardiography (Echo) were regularly assessed before each course of chemotherapy. The cardiac disorders were diagnosed according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Binary logistic regression analysis was used to identify risk factors associated with cardiac disorders. There were 171 children eligible for the study, and 78 patients (45.61%) were confirmed as having cardiac disorders. The incidence of cardiac disorders was dependent upon the cumulative dose of daunorubicin (DNR) (<jats:italic>p<\/jats:italic> = 0.030, OR = 1.553, 95% CI: 1.005\u20133.108). Four patients (2.34%) presented with palpitation, chest pain, and persistent tachycardia, and they were cured or improved after medical intervention. A total of 74 patients (43.27%) had subclinical cardiac disorders confirmed by ECG or Echo. ECG abnormalities were commonly seen in the induction and continuation treatments, including arrhythmias (26, 15.20%), ST changes (24, 14.04%) and conduction disorders (4, 2.34%). Pericardial effusion (14, 8.19%), left ventricular hypertrophy (11, 6.43%), a widened pulmonary artery (5, 2.92%) and valvular insufficiency (5, 2.92%) suggested by Echo occurred after induction chemotherapy. Therefore, cardiac disorders with clinical manifestations are rare and need early intervention. Subclinical cardiac disorders are common but very hidden in children during ALL chemotherapy. Regular ECG and Echo could help paediatricians to identify and monitor patients with asymptomatic cardiac disorders earlier.<\/jats:p>","DOI":"10.3389\/fphar.2021.598708","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T06:20:56Z","timestamp":1616998856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Anthracycline Induced Cardiac Disorders in Childhood Acute Lymphoblastic Leukemia: A Single-Centre, Retrospective, Observational Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Hui","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhujun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"B16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ppedcard.2014.09.003","article-title":"Late cardiotoxicity in aging adult survivors of childhood cancer","volume":"36","author":"Armstrong","year":"2014","journal-title":"Prog. Pediatr. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: Part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"B24","first-page":"75","article-title":"Chemotherapy and cardiotoxicity","volume":"9","author":"Broder","year":"2008","journal-title":"Rev. Cardiovasc. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/archdischild-2018-316181","article-title":"Treatment abandonment in childhood acute lymphoblastic leukemia in China: a retrospective cohort study of the Chinese children\u2019s cancer group","volume":"104","author":"Cai","year":"2019","journal-title":"Arch. Dis. Child."},{"key":"B5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3969\/j.issn.1009-0460.2013.10.014","article-title":"Guidelines for the prevention and treatment of cardiotoxicity of anthracyclines","year":"2013","journal-title":"Chin. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3904\/kjim.2016.017","article-title":"Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity","volume":"31","author":"Chung","year":"2016","journal-title":"Korean J. Intern. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.15420\/cfr.2018.32.2.e","article-title":"Heart failure and cancer: mechanisms of old and new cardiotoxic drugs in cancer patients","volume":"5","author":"Cuomo","year":"2019","journal-title":"Card Fail. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1309\/AJCPB66LRIIVMQDR","article-title":"Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use","volume":"130","author":"Dolci","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1389200218666171101124931","article-title":"Pharmacogenetics of metabolic genes of anthracyclines in acute myeloid leukemia","volume":"19","author":"Eduardo","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/134679","article-title":"Cardiovascular effects in childhood cancer survivors treated with anthracyclines","volume":"2011","author":"Franco","year":"2011","journal-title":"Cardiol. Res. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1081\/cnv-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2017","journal-title":"Heart"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1038\/cddis.2011.65","article-title":"Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity","volume":"2","author":"Huelsenbeck","year":"2011","journal-title":"Cell Death Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"377","author":"Jensen","year":"2011","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Joerg","year":"2014","journal-title":"Mayo Clinic Proc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1200\/JCO.2008.21.1813","article-title":"Pediatric cancer survivorship research: experience of the childhood cancer survivor study","volume":"27","author":"Leisenring","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1200\/JCO.2009.26.5751","article-title":"Cardiotoxicity after childhood cancer: beginning with the end in mind","volume":"28","author":"Lipshultz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/pbc.24597","article-title":"Cardiotoxicity in childhood cancer survivors: a problem with long-term consequences in need of early detection and prevention","volume":"60","author":"Lipshultz","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ppedcard.2014.09.007","article-title":"Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence","volume":"36","author":"Lipshultz","year":"2014","journal-title":"Prog. Pediatr. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/1389200013338243","article-title":"Contribution of specific transport systems to anthracycline transport in tumor and normal cells","volume":"2","author":"Nagasawa","year":"2001","journal-title":"Curr. Drug Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3322\/canjclin.54.4.208","article-title":"Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors","volume":"54","author":"Oeffinger","year":"2004","journal-title":"CA Cancer J. Clin."},{"key":"B35","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s00392","article-title":"Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity","volume":"108","author":"Ohtani","year":"2019","journal-title":"Clinical Research in Cardiology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archinternmed.2010.233","article-title":"Cardiac function in 5-year survivors of childhood cancer","volume":"170","author":"Pal","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1200\/JCO.2009.22.3339","article-title":"The childhood cancer survivor study: a national cancer institute-supported resource for outcome and intervention research","volume":"27","author":"Robison","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.acmx.2013.08.006","article-title":"Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist","volume":"84","author":"Salazar-Mendiguch\u00eda","year":"2014","journal-title":"Arch. Cardiol. Mex"},{"key":"B31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"B1","doi-asserted-by":"publisher","first-page":"30186","DOI":"10.1016\/S14702045","article-title":"International incidence of childhood cancer, 2001\u201310: a population-based registry study","volume":"17","author":"Steliarova-Foucher","year":"2017","journal-title":"Lancet Oncol."},{"key":"B50","year":"2017","journal-title":"Common terminology criteria for adverse events (CTCAE) v5.0"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"B19","first-page":"71","article-title":"[Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases]","volume":"13","author":"Wang","year":"1991","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00392-019-01417-x","article-title":"Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer","volume":"108","author":"Yoon","year":"2019","journal-title":"Clin. Res. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.598708\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T06:21:01Z","timestamp":1616998861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.598708\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":35,"alternative-id":["10.3389\/fphar.2021.598708"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.598708","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"article-number":"598708"}}